---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-031463"
form_type: "8-K"
ticker: "CING"
cik: "0001862150"
company_name: "Cingulate Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:50:35.519845+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cingulate Q2 net loss narrows to $3.2M; FDA clears NDA filing for ADHD drug CTx-1301

## Summary
- Net loss of $3.2M in Q2 2024 vs $6.6M in Q2 2023; R&D expenses fell to $1.9M from $4.5M YoY.
- Cash and equivalents $0.4M at June 30; received $1.6M net proceeds from warrant inducement closed July 1.
- FDA confirmed remaining clinical requirements; NDA submission for CTx-1301 targeted for first half 2025.
- Completed 1-for-12 reverse stock split on Aug 9 to regain compliance with Nasdaq $1.00 bid price rule.
- Commissioned payer study (10 payers, 121M lives) found CTx-1301 likely to gain coverage; licensing discussions ongoing.

## SEC filing metadata
- accession: 0001493152-24-031463
- form_type: 8-K
- ticker: CING
- cik: 0001862150
- company_name: Cingulate Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1862150/000149315224031463/0001493152-24-031463-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1862150/000149315224031463/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-031463
- JSON: https://secwatch.observer/filing/0001493152-24-031463.json
- Plain text: https://secwatch.observer/filing/0001493152-24-031463.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.